

1340-1-016N

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Rodger Novak et al.

SERIAL NO. :

09/305,984

**EXAMINER**:

LEE, L.

**FILED** 

May 5, 1999

**ART UNIT** 

1645

**FOR** 

NOVEL ANTIBIOTICS AND METHODS OF USE THEREOF

## **Certificate of Mailing Under 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 on January 10, 2000

Michael D. Davis, Reg. No. 39,161

(Name of Registered Rep.)

## RESPONSE TO REQUIREMENT FOR RESTRICTION UNDER 35 U.S.C. §121

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Dear Sir:

Responsive to the Office Action dated November 9, 1999, issued in connection with the above-identified Application, which is now due for response with a month extension on January 10, 2000 since January 9 falls on a Sunday, please consider the following remarks. Applicants also submit a copy of the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures along with a Substitute computer readable form of the Sequence Listing and a Statement in Support of the Filing.

## REMARKS

By this Office Action, the Examiner has required restriction to one of the following inventions under 35 U.S.C. §121: